BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 32048058)

  • 1. Current State of Systemic Therapies for Advanced Renal Cell Carcinoma.
    Gulati S; Vaishampayan U
    Curr Oncol Rep; 2020 Feb; 22(3):26. PubMed ID: 32048058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors.
    Biles MJ; Patel HD; Allaf ME
    Urol Clin North Am; 2020 Aug; 47(3):359-370. PubMed ID: 32600537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
    Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
    Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.
    Reed JP; Posadas EM; Figlin RA
    Expert Rev Anticancer Ther; 2019 Mar; 19(3):259-271. PubMed ID: 30669895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome benefits of upfront cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: An analysis of the TriNetX database.
    Lai GS; Li JR; Wang SS; Chen CS; Yang CK; Lin CY; Hung SC; Chiu KY; Yang SF
    PLoS One; 2024; 19(3):e0299102. PubMed ID: 38547226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
    Yanagisawa T; Schmidinger M; Kawada T; Bekku K; Kimura T; Shariat SF
    Eur Urol Focus; 2023 Mar; 9(2):275-277. PubMed ID: 36775716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Liu J; Moon D; Lawrentschuk N
    Eur Urol; 2023 Aug; 84(2):244-245. PubMed ID: 37088596
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is cytoreductive nephrectomy relevant in the immunotherapy era?
    Singla N; Ghandour RA; Margulis V
    Curr Opin Urol; 2019 Sep; 29(5):526-530. PubMed ID: 31305273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions.
    Merza H; Bilusic M
    Curr Oncol Rep; 2017 Apr; 19(4):27. PubMed ID: 28303494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type.
    Parikh M; Lara PN
    Annu Rev Med; 2018 Jan; 69():209-221. PubMed ID: 29144835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
    Gill DM; Hahn AW; Hale P; Maughan BL
    Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.
    Albiges L; Choueiri T; Escudier B; Galsky M; George D; Hofmann F; Lam T; Motzer R; Mulders P; Porta C; Powles T; Sternberg C; Bex A
    Eur Urol; 2015 Jan; 67(1):100-110. PubMed ID: 24841777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances and future directions in the management of metastatic renal cell carcinoma.
    Ansari J; Glaholm J; McMenemin R; James ND; Hussain SA
    Anticancer Agents Med Chem; 2010 Mar; 10(3):225-35. PubMed ID: 20184547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Position of cytoreductive nephrectomy in the setting of metastatic renal cell carcinoma patients: does the CARMENA trial lead to a paradigm shift?
    Dariane C; Timsit MO; Méjean A
    Bull Cancer; 2018 Dec; 105 Suppl 3():S229-S234. PubMed ID: 30595151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?
    Pignot G; Thiery-Vuillemin A; Walz J; Lang H; Bigot P; Werle P; Balssa L; Geoffrois L; Leblanc L; Albigès L; di Nunno V; Bensalah K; Ladoire S; Gravis G; Barthélémy P
    Eur Urol; 2020 Jun; 77(6):761-763. PubMed ID: 31911011
    [No Abstract]   [Full Text] [Related]  

  • 18. The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age.
    Huang JJ; Hsieh JJ
    Semin Nephrol; 2020 Jan; 40(1):28-41. PubMed ID: 32130964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
    de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
    Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER].
    Nosov AK; Novik AV; Vorobiev AV; Samartseva EE; Reva SA; Baldueva IA; Lushina PA
    Vopr Onkol; 2015; 61(3):494-8. PubMed ID: 26242167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.